The animal model for experimental encephalomyelitis, first published 90 yr ago, continues to illuminate mechanisms of disease. The model, initially developed to
Rescooped by
Gilbert C FAURE
from NeuroImmunology
onto History of Immunology |
Experimental autoimmune encephalomyelitis (EAE) has been catalytic for the development of therapeutic breakthroughs for multiple sclerosis (MS), including the first synthetic peptide–based polymer for MS, the first monoclonal antibody therapy for MS, and the first oral therapy for MS. EAE has also illuminated important mechanisms for immune tolerance, and the model has provided seminal observations on the impact of the microbiome on autoimmune disease. Before describing those important breakthroughs in therapeutics and the insights into the basic mechanisms underlying autoimmunity, where the EAE model provided the stage for the initial discoveries, we shall describe the various models themselves, collectively termed EAE.